Listen: The decade in breakthrough drugs & the year in bad CEOing – STAT
STAT’s Matthew Herper joins us to discuss the most important drugs of the past decade, including treatments for hepatitis C, cystic fibrosis, and cancer.
Related Articles
UnitedHealthcare rolls out new therapy restrictions for Medicare Advantage plans
As of Sept. 1, Medicare Advantage members who need PT, OT, or ST in a physician’s office will need approval from UnitedHealthcare. This will create…
130,000 U.S. cancer cases went undiagnosed in Covid pandemic, study finds
130,000 U.S. cancer cases went undiagnosed in the Covid pandemic. Experts still don’t know what happened to them.
In children, Covid is tied to higher risk of type 2 diabetes
It may be time to add Covid-19 infection to the list of possible risk factors for developing type 2 diabetes at a young age. An…
Yes on abortion, no on Tester? A Democratic senator’s struggle underscores his party’s conundrum
Montana’s role as a safe haven for abortion care in the rural West is at stake in November’s election.
2024 STAT Summit
The STAT Summit is back in Boston October 16 & 17, 2024 — this year we’re examining change in medicine, why it’s so hard, &…
Morning Rounds: Why aren’t we doing better on cardiovascular health?
Today’s health news includes how the U.S. primary care crisis is hurting the fight against heart disease, the Nobel gender gap, and more.
The biotech news you missed this weekend
Just in the first half of 2024, over $1.7 billion was committed to autoimmune disease research. The influx is driven largely by breakthroughs in CAR-T…
What the Sandoz CEO is thinking about the 2024 elections
“Railing against ‘Big Pharma’ while failing to support the market for generic and biosimilar medicines is missing the forest for the trees,” writes Sandoz CEO…
Heart disease experts in their own words: ‘This is solvable and this is preventable’
Experts tell STAT what’s keeping Americans from reaching better cardiovascular health — and what’s giving them hope.
11 experts on why gains in cardiovascular disease are stalling and what we can do about it
STAT asked 11 experts, including the FDA commissioner, why the world’s wealthiest nation is doing so poorly on cardiovascular health.